Overview

Combination of Methotrexate(MTX) and Actinomycin(ACTD) in the Low Risk Gestational Trophoblastic Neoplasma （GTN） Patients With Score of 5-6

Status:
Recruiting

Trial end date:
2023-12-31

Target enrollment:

Participant gender:

Summary

In this study, a prospective, multicenter randomized controlled study was conducted to compare the clinical efficacy and toxicity response of combination MTX+ACTD multi-course regimen in low-risk GTN patients with score 5-6 with standard MTX single-drug multi-course regimen.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Women's Hospital School Of Medicine Zhejiang University

Collaborators:

Huazhong University of Science and Technology
Qilu Hospital of Shandong University
West China Second University Hospital

Treatments:

Dactinomycin
Methotrexate